Sangamo Therapeutics, Inc. (SGMO)Healthcare | Biotechnology | Richmond, United States | NasdaqCM
0.26 USD
-0.01
(-2.963%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.27 +0.01 (3.015%) ⇧ (April 17, 2026, 7:48 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:35 p.m. EDT
Despite a bullish analyst target consensus, the on-the-ground data tells a strongly bearish tale. The stock is tracking the $0.21-0.26 range, well below its $0.35 50-day average, while suffering from negative breadth and heavy options hedging in the $1.00 strike. The lack of put volume expiring in a month before the earnings date suggests speculators are 'selling the news' or exiting positions rather than setting stops. Fundamentally, with -$56M cash burn, negative operating cash flow, and a recent earnings miss, SGMO is currently a cash-burning biotech stock with no dividend support, making this a low-conviction hold at worst. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.116176 |
| MSTL | 0.121969 |
| AutoETS | 0.123799 |
| AutoARIMA | 0.126446 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 66% |
| H-stat | 1.50 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.695 |
| Excess Kurtosis | 0.49 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.141 |
| Market Cap | 108,539,792 |
| Forward P/E | Infinity |
| Beta | 1.50 |
| Website | https://www.sangamo.com |
As of April 18, 2026, 10:35 p.m. EDT: Options flow indicates aggressive positioning for downside protection. In the near term (April expiration), Put OI is effectively zero, suggesting limited hedging pressure for the immediate launch week, but Call volume is heavily concentrated in ATM strikes (0.5 strike). Longer-term expirations show significant volume and Open Interest in ITM puts (Jan 2707 strike), specifically the $1.00 strike which has high OI relative to volatility, signaling a 'black swan' hedge or settlement guarantee below current levels. The Call market is consistently out-of-the-money, suggesting speculative bets for a rebound are capped by this put barrier.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6486486 |
| Address1 | 501 Canal Blvd |
| All Time High | 51.375 |
| All Time Low | 0.21 |
| Ask | 0.3059 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 5,378,260 |
| Average Daily Volume3 Month | 6,866,835 |
| Average Volume | 6,866,835 |
| Average Volume10Days | 5,378,260 |
| Beta | 1.503 |
| Bid | 0.2296 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | -0.041 |
| City | Richmond |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.262 |
| Current Ratio | 0.844 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.284 |
| Day Low | 0.262 |
| Display Name | Sangamo Therapeutics |
| Earnings Call Timestamp End | 1,774,902,600 |
| Earnings Call Timestamp Start | 1,774,902,600 |
| Earnings Timestamp | 1,774,900,800 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -104,043,000 |
| Ebitda Margins | -2.63054 |
| Enterprise To Ebitda | -1.099 |
| Enterprise To Revenue | 2.892 |
| Enterprise Value | 114,386,792 |
| Eps Current Year | -0.26 |
| Eps Forward | 0.0 |
| Eps Trailing Twelve Months | -0.44 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.352 |
| Fifty Day Average Change | -0.09 |
| Fifty Day Average Change Percent | -0.25568184 |
| Fifty Two Week Change Percent | -64.86486 |
| Fifty Two Week High | 0.84 |
| Fifty Two Week High Change | -0.57799995 |
| Fifty Two Week High Change Percent | -0.6880952 |
| Fifty Two Week Low | 0.21 |
| Fifty Two Week Low Change | 0.052 |
| Fifty Two Week Low Change Percent | 0.24761906 |
| Fifty Two Week Range | 0.21 - 0.84 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 955,027,800,000 |
| Float Shares | 406,771,515 |
| Forward Eps | 0.0 |
| Forward P E | Infinity |
| Free Cashflow | -56,760,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 142 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | -1.8486501 |
| Gross Profits | -73,118,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01741 |
| Held Percent Institutions | 0.15325 |
| Implied Shares Outstanding | 414,274,017 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California. |
| Long Name | Sangamo Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 108,539,792 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_412674 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -122,932,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 108,539,792 |
| Number Of Analyst Opinions | 4 |
| Open | 0.2759 |
| Operating Cashflow | -97,208,000 |
| Operating Margins | -1.75485 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 510 970 6000 |
| Post Market Change | 0.0079 |
| Post Market Change Percent | 3.0152671 |
| Post Market Price | 0.2699 |
| Post Market Time | 1,776,469,730 |
| Previous Close | 0.27 |
| Price Eps Current Year | -1.0076923 |
| Price Hint | 4 |
| Price To Book | -6.3902435 |
| Price To Sales Trailing12 Months | 2.7442303 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.741 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.00800002 |
| Regular Market Change Percent | -2.96297 |
| Regular Market Day High | 0.284 |
| Regular Market Day Low | 0.262 |
| Regular Market Day Range | 0.262 - 0.284 |
| Regular Market Open | 0.2759 |
| Regular Market Previous Close | 0.27 |
| Regular Market Price | 0.262 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 3,104,485 |
| Return On Assets | -0.83656996 |
| Return On Equity | -28.91837 |
| Revenue Growth | 0.884 |
| Revenue Per Share | 0.141 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 414,274,017 |
| Shares Percent Shares Out | 0.0908 |
| Shares Short | 37,605,702 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 33,065,989 |
| Short Name | Sangamo Therapeutics, Inc. |
| Short Percent Of Float | 0.091400005 |
| Short Ratio | 6.15 |
| Source Interval | 15 |
| State | CA |
| Symbol | SGMO |
| Target High Price | 10.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 3.75 |
| Target Median Price | 2.0 |
| Total Cash | 20,948,000 |
| Total Cash Per Share | 0.051 |
| Total Debt | 26,795,000 |
| Total Revenue | 39,552,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.47675 |
| Two Hundred Day Average Change | -0.21474999 |
| Two Hundred Day Average Change Percent | -0.4504457 |
| Type Disp | Equity |
| Volume | 3,104,485 |
| Website | https://www.sangamo.com |
| Zip | 94,804 |